Introduction The purpose of this study is to compare the effect of increasing concentrations of
direct anti‐Xa oral anticoagulants (DOAC) apixaban‐, edoxaban‐, and rivaroxaban …

Background: Oral anti-Xa inhibitors have demonstrated noninferiority to vitamin K
antagonists (VKAs) for the prevention of stroke in patients with atrial fibrillation and recurrent …

A universal anti‐Xa assay for the determination of rivaroxaban, apixaban and edoxaban
drug concentrations would simplify laboratory procedures and facilitate widespread …

Several new oral anticoagulants such as rivaroxaban (which targets Factor Xa) and
dabigatran etexilate (which targets thrombin) are in advanced stages of clinical development …

Possibilities to monitor rivaroxaban therapy could be useful in certain circumstances.
Prothrombin time (PT) or chromogenic anti-Xa assays such as the Biophen Direct Factor Xa …

Essentials• The value of thrombin generation assay (TGA) in monitoring direct oral
anticoagulants (DOAC) is not well defined.• TGA parameters were measured and correlated …

Direct oral anticoagulants (DOACs) do not require frequent monitoring as vitamin K
antagonists (VKA) but an assessment of the intensity of anticoagulation may be required in …

What is already known about this subject• Rivaroxaban is a novel anticoagulant with
predictable, dose‐proportional pharmacokinetics and pharmacodynamics in healthy …

Rivaroxaban is an oral direct factor Xa inhibitor, therapeutically indicated in the treatment of
thromboembolic diseases. As other new oral anticoagulants, routine monitoring of …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Rivaroxaban is an oral, direct Factor
Xa inhibitor in advanced clinical development for the prevention and treatment of …